Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Fresenius Medical Care Corp (FMS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,504,642
  • Shares Outstanding, K 613,692
  • Annual Sales, $ 20,101 M
  • Annual Income, $ 1,447 M
  • 36-Month Beta 1.34
  • Price/Sales 1.23
  • Price/Cash Flow 10.73
  • Price/Book 1.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.64
  • Number of Estimates 1
  • High Estimate 0.64
  • Low Estimate 0.64
  • Prior Year 0.69
  • Growth Rate Est. (year over year) -7.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.53 +15.41%
on 01/24/19
40.27 -1.04%
on 02/20/19
+4.70 (+13.37%)
since 01/18/19
3-Month
30.99 +28.59%
on 01/03/19
41.90 -4.89%
on 12/03/18
+1.31 (+3.40%)
since 11/21/18
52-Week
30.99 +28.59%
on 01/03/19
54.81 -27.29%
on 02/26/18
-13.62 (-25.47%)
since 02/21/18

Most Recent Stories

More News
CytoSorbents Announces Expansion of CytoSorb® Partnership with Fresenius Medical Care

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery...

CTSO : 8.23 (+1.60%)
FMS : 39.85 (-0.20%)
New Strong Sell Stocks for January 16th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

BDC : 60.34 (-5.38%)
CS : 11.89 (-1.08%)
GVA : 46.81 (-3.35%)
FDX : 182.28 (+0.20%)
FMS : 39.85 (-0.20%)
New Strong Sell Stocks for January 9th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

AZZ : 47.50 (-1.72%)
GDEN : 17.96 (-0.39%)
CHCT : 34.69 (-0.91%)
ALV : 79.32 (-4.17%)
FMS : 39.85 (-0.20%)
Baxter's PD Solution to Treat Patients, Prospects Bright

Baxter's (BAX) kidney care portfolio likely to favor the company as kidney care demand shoots up in the United States.

VEEV : 116.85 (-0.97%)
BAX : 74.03 (-0.13%)
FMS : 39.85 (-0.20%)
DVA : 59.21 (+0.25%)
Cara (CARA) Up on IDMC's Recommendation to Continue Trial

Cara (CARA) gains after IDMC recommended the late-stage trial on lead drug, Korsuva, to continue without any modifications.

CARA : 16.64 (+0.60%)
MNK : 20.52 (-3.30%)
PCRX : 39.61 (-1.59%)
FMS : 39.85 (-0.20%)
Recent Analysis Shows LiveRamp, Five Point, Corporate Capital Trust, Fresenius Medical Care AG & Co. KGaA, Lsb Industries, and Telefonica Brasil S.A Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of LiveRamp Holdings, Inc. (NYSE:RAMP),...

VIV : 12.65 (-0.63%)
RAMP : 51.71 (-0.21%)
CCT : 12.35 (-4.11%)
LXU : 7.70 (+0.79%)
FMS : 39.85 (-0.20%)
FPH : 8.15 (+1.62%)
Capital Square 1031 Completes Diversified DST Offering of Nine Medical Office Buildings in Five States

Capital Square 1031, a leading sponsor of Delaware statutory trust investments, announced today that CS1031 Diversified Dialysis Portfolio, DST, comprised of nine medical office buildings in five states,...

FMS : 39.85 (-0.20%)
Fresenius Medical (FMS) Beats on Q3 Earnings, Lags Revenues

Lower North America sales hurt Fresenius Medical's (FMS) Q3 results. Care Coordination margin improves significantly.

MMSI : 59.94 (-1.54%)
SYK : 187.58 (-0.03%)
FMS : 39.85 (-0.20%)
ISRG : 549.87 (+0.04%)
Today's Research Reports on Stocks to Watch: Fresenius Medical Care and Oragenics

NEW YORK, NY / ACCESSWIRE / October 18, 2018 / Oragenics was gaining on Wednesday after announcing it has received clearance to enroll patients into a Phase 2 clinical trial. Shares of Fresenius Medical...

FMS : 39.85 (-0.20%)
Here's Why You Should Sell Fresenius Medical (FMS) Stock Now

A rapidly changing healthcare environment in the United States, sluggish Q1 and competition in the niche markets are major headwinds for Fresenius Medical (FMS).

GHDX : 78.35 (-6.35%)
ABMD : 358.36 (-1.07%)
EXEL : 21.22 (-0.09%)
FMS : 39.85 (-0.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade FMS with:

Business Summary

Fresenius Medical Care provides a range of products for both treatment modalities, hemmodialysis and peritoneal dialysis, and is a full service provider of dialysis care. They provide dialysis treatment and related laboratory and diagnostic services at more than 1,000 dialysis clinics. They manufacture...

See More

Key Turning Points

2nd Resistance Point 40.14
1st Resistance Point 40.00
Last Price 39.85
1st Support Level 39.70
2nd Support Level 39.54

See More

52-Week High 54.81
Fibonacci 61.8% 45.71
Fibonacci 50% 42.90
Fibonacci 38.2% 40.09
Last Price 39.85
52-Week Low 30.99

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar